Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• Type I interferons (IFNs) are crucial for antiviral defense by inducing IFN-stimulated genes and modulating immune responses.
• Prolonged activity of interferon-alpha (IFN-α) in persistent infections like HIV can lead to detrimental immune activation and impaired immune cell function.

Purpose of the Study:

• To investigate the dual role of IFN-α in HIV infection and disease progression.
• To explore the impact of IFN-α on immune activation and age-related comorbidities in HIV patients undergoing antiretroviral therapy (ART).
• To highlight the need for better methods to assess IFN-α activity in clinical settings for improved HIV management.

Main Methods:

• Review of existing literature on Type I IFNs, HIV infection, and immune responses.
• Analysis of the effects of IFN-α on monocytes, T lymphocytes, and B lymphocytes in the context of chronic viral infections.
• Discussion of therapeutic strategies involving IFN-α and IFN-α inhibitors for HIV management.

Main Results:

• IFN-α exhibits both beneficial antiviral effects and detrimental immunomodulatory effects in persistent HIV infection.
• Increased IFN-α activity is linked to monocyte activation, contributing to comorbidities like atherosclerotic and brain diseases in HIV patients on ART.
• IFN-α therapy may aid HIV eradication, while IFN-α inhibitors are explored for treating immune activation.

Conclusions:

• Understanding the opposing effects of IFN-α is critical for optimizing the management of HIV patients on ART.
• Developing clinical methods to assess IFN-α activity can improve treatment strategies and patient outcomes.
• Further research is needed to balance the therapeutic benefits and risks of IFN-α in HIV management.